MENU
PHIO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Phio Pharmaceuticals (PHIO) Ownership - Who owns Phio Pharmaceuticals?
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
11 Apex Drive
Phone
+1 508 767-3861
Employees
9
Web
https://www.phiopharma.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
10.6M
P/E Ratio
0.01
Total Cash
13.28M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
1.10
Dividend Yield
N/A
Total Cash/Share
2.77
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
PHIO
Capitalization
10.6M
P/E Ratio
0.01
Risk (Beta)
1.10
Dividend Yield
N/A
Total Cash
13.3M
Total Cash/Share
2.77
Total Debt
0
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
12.2M
P/B Ratio
0.87
Cash Flow
N/A
Earnings
-9.02
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
10.58
Current Revenue Per Employee
2333.33
Dividends Per Share - Security
N/A
EBITDA
-7.05M
Float
N/A
Float - Current
N/A
Gross Income Margin
100.00
Revenue To Assets
-66.67
Shares Held By Institutions
270K
Shares Outstanding - Current
4.8M
Total Liabilities
1.27M
Total Volume MTD
N/A
Value
N/A
Gain YTD
22.778
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of RNAi-based medical technologies and therapies
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Apex Drive
Phone
+1 508 767-3861
Employees
9
Web
https://www.phiopharma.com